Antibody discovery is at the core of therapeutics research. VHH antibodies, also known as single-domain antibodies, offer a smaller, engineerable alternative to traditional antibodies, overcoming many of their limitations.

In this eBook, in partnership with Abcore (CA, USA), a Fortis Life Sciences^TM (MA, USA) company, we highlight how VHH antibodies are being developed and harnessed for therapeutic purposes, delving into the scaffolds used to generate and discover them and examples of their real-world applications against disease.

DOWNLOAD NOW

Contents

• Introduction
• Editorial: IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents
• Poster: Nanomolar VHH binders of PD-L1 and other therapeutic targets from the AbNano^TM VHH Naive Library
• Research Article: Chimeric antigens displaying GPR65 extracellular loops on a soluble scaffold enabled the discovery of antibodies, which recognized native receptor
• Original Article: Development and utilization of VHH antibodies derived from Camelus Dromedarius against foot-and-mouth disease virus
• White Paper: VHH antibodies: novel engineering strategies beget diverse applications

This eBook was supported by Abcore.